Prostate cancer (PC) is the most common malignancy diagnosed among men, with over one million new cases reported worldwide annually \[[@cit0001]\]. Patients with clinically localized low-risk prostate cancer (CL-LRPC) are at low risk of cancer progression and account for approximately one third of newly diagnosed PC cases \[[@cit0002]\]. This patient population is eligible for active surveillance (AS), as recommended by most world guidelines \[[@cit0003]--[@cit0008]\]. which entails actively monitoring the disease with a plan to deliver curative intent-therapy upon PC progression. The goal of AS is to defer treatment for CL-LRPC in order to mitigate potential treatment-related side effects, in most cases indefinitely. However, despite widespread and increasing adoption of AS for LR-CLPC \[[@cit0009]\], there is substantial heterogeneity in AS protocols among clinical practice guidelines. Overall, this suggests a paucity in literature with regards to optimal evidence-based surveillance strategies.

There are several components of AS protocols, which includes: serum prostate specific antigen (PSA) monitoring, periodic digital rectal examination (DRE), transrectal or transperineal prostate biopsy (TRUS-Bx), and multiparametric magnetic resonance imaging (mpMRI) of the prostate. [Table 1](#t0001){ref-type="table"} summarizes several AS protocols for patients with CL-LRPC published by various professional organizations. As of now, there is no universally accepted consensus with regards to recommended frequency of surveillance and the timing of repeat biopsy. For example, confirmatory biopsy is recognized as a standard protocol by several North American guidelines, but not routinely recommended by the UK National Institute for Health and Care Excellence (NICE) \[[@cit0008]\] or by recently updated European Association of Urology guidelines \[[@cit0003]\]. Overall, as compared to European guidelines, in Canada and United States most patients are followed with more stringent protocols which entail PSA screening every 6 months, DRE every 12 months, and repeat TRUS-Bx every 2-5 years \[[@cit0005], [@cit0007]\].

###### 

Summary of guidelines on management of active surveillance in prostate cancer

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors               PSA                                                  DRE                                             Prostate biopsy                                          mpMRI                                                         Initiation of active treatment                                                   Terminating AS                                                                                                
  --------------------- ---------------------------------------------------- ----------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -----------------------------------------------
  EAU \[[@cit0003]\]    every 6 months                                       every 12 months                                 timing not specified[^e^](#tf1-4){ref-type="table-fn"}   not routinely recommended[^f^](#tf1-5){ref-type="table-fn"}   before confirmatory biopsy                                                       decision based on a change in the biopsy results or T-stage progression                                       N/A

  NCCN \[[@cit0004]\]   every ≥6 months                                      every ≥12 months                                within 6 months[^c^](#tf1-3){ref-type="table-fn"}        every ≥12 months                                              as an optional confirmatory tool at enrollment, repeated every ≥ 12 months       Gleason pattern 4 or 5 at biopsy or an increase in number of cores involved or in core length involvement     \<10-year life expectancy (end serial biopsy)

  CCO \[[@cit0005]\]    every 3--6 months                                    every 12 months                                 within 6-12 months                                       every 3--5 years                                              indicated when clinical findings discordant with the pathologic findings         Gleason score ≥7 (if Gleason pattern 4 \>10% total cancer) or significant increases in the volume of cancer   turning 80-year-old (end serial biopsy)

  ASCO \[[@cit0006]\]   every 3--6 months                                    every ≤12 months                                within 6--12 months                                      every 2--5 years                                              indicated when clinical findings discordant with the pathologic findings         Gleason score ≥7 or significant increases in the volume of cancer                                             in men with limited life expectancy

  AUA \[[@cit0007]\]    unspecified[^d^](#tf1-4){ref-type="table-fn"}        unspecified[^d^](#tf1-4){ref-type="table-fn"}   within 24 months                                         unspecified[^d^](#tf1-4){ref-type="table-fn"}                 may be included into the protocol, should be performed on at minimum\            clinical upstaging or upgrading at subsequent biopsy                                                          N/A
                                                                                                                                                                                                                                                    a 1.5 T magnet and reviewed by an experienced radiologist                                                                                                                                      

  NICE \[[@cit0008]\]   every 3-6 months[^a^](#tf1-1){ref-type="table-fn"}   every 12 months                                 not recommended[^b^](#tf1-2){ref-type="table-fn"}        not routinely recommended[^f^](#tf1-4){ref-type="table-fn"}   offer to mpMRI-naïve patients; perform at 12--18 months of active surveillance   evidence of disease progression -- not specified                                                              N/A
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

every 3--4 months in the first year, every 6 months thereafter

according to the guideline all men diagnosed with prostate cancer should have had an mpMRI-guided biopsy performed prior to the diagnosis; if not, an mpMRI should be offered and an mpMRI-guided biopsy performed if the results are discordant with the initial biopsy findings

not obligatory, should be performed if initial biopsy was \<10 cores or assessment discordant (eg. contralateral tumor on DRE)

although serial testing with this tool is recommended, no specific time interval is provided in the guideline

weak recommendation: no need for confirmatory biopsy if the primary biopsy was a targeted mpMRI-guided biopsy

should be performed in case if progression suspected (based on PSA, DRE, or mpMRI)

PSA -- prostate-specific antigen, DRE -- digital rectal examination, mpMRI -- multiparametric magnetic resonance imaging, AS -- active surveillance, EAU -- European Associoation of Urology, NCCN -- National Comprehensive Cancer Network, CCO -- Cancer Care Ontario, ASCO -- American Society of Clinical Oncology, AUA -- American Urology Association, NICE -- National Institute for Health and Care Excellence, N/A -- not available

As shown in [Table 2](#t0002){ref-type="table"}, in the recent years many centers from around the world have published their experience with AS for CL-LRPC, reporting promising outcomes with low rates of adverse events \[[@cit0010]--[@cit0018]\]. However, due to heterogeneity among clinical practice guidelines, clinicians considering AS as a treatment strategy may be uncertain as to which surveillance strategies to adopt. In our opinion, one of the primary goals for improving the quality of care for patients on AS is to develop and recommend a precise, uniform, and standardized evidence-based protocol. It is likely that the optimal approach will be risk stratified. In order to achieve this goal, we believe that future research should focus on: (1) systematic analysis of all available evidence regarding the outcomes of employing each protocol, (2) even more extensive research into the natural history of low-risk prostate cancer and the role of each element of the protocol in detecting progression of the disease, (3) developing new tools (eg. molecular testing, novel imaging) or expanding the role of existing ones (especially mpMRI), and (4) further prospective evaluation of specific protocols within clinical studies. An AS strategy that encompasses these areas of research must be conscious of resource constraints and cost effectiveness.

###### 

Summary of outcomes of recent, large observational studies on active surveillance for prostate cancer

  Studies                             Year   Number of patients   Median Age (years)   Median PSA at baseline (ng/ml)                                      Median follow up (months)                                                               Overall survival (%)                                                                                  Cancer-specific survival (%)              Curative intervention rate   On active surveillance (%)                          Death from prostate cancer -- related cause
  ----------------------------------- ------ -------------------- -------------------- ------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------- ---------------------------- --------------------------------------------------- ---------------------------------------------
  Thompson et al. \[[@cit0010]\]      2015   650                  63                   6.2                                                                 55                                                                                      NR                                                                                                    100 at median follow up                   6.2 y: 38%                   43.5 (≤12 cores) 56.2 (\>12 cores)                  0
  Welty et al. \[[@cit0011]\]         2015   556                  62                   5.3                                                                 60                                                                                      98 (at 5 years)                                                                                       100% (at 5 years)                         5 y: 40% 10 y: 50%           40[^a^](#tf2-1){ref-type="table-fn"}                0
  Tosoian et al. \[[@cit0012]\]       2015   1,298                66                   4.8                                                                 60                                                                                      93 (at 10 years) 69 (at 10 years)                                                                     99.9 (at 10 years) 99.9 (at 10 years)     10 y: 50% 15 y: 57%          50 (at median follow up)                            2
  Klotz et al. \[[@cit0013]\]         2015   993                  67.8                 \<2.5 in 14% 2.5--5 in 30% 5--10 in 43% \>10 in 11% Unknown in 2%   \>72                                                                                    80 (at 10 years) 62 (at 15 years)                                                                     98.1 (at 10 years) 94.3 (at 15 years)     10 y: 36% 15 y: 45%          75.7 (at 5 years)                                   15
  Godtman et al. \[[@cit0014]\]       2016   474                  66                   NR                                                                  96                                                                                      80 (at 10 years) 51 (at 105 years)                                                                    99.5% (at 10 years) 96% (at 15 years)     10 y: 53% 15 y: 66%          57                                                  6
  Bokhorst et al. \[[@cit0015]\]      2016   5,302                65.9                 5.7                                                                 622 were followed on active surveillance \> 5 years 107 were followed for \>7.5 years   97 (at 5 years) 89 (at 10 years)                                                                      99% (at 5 years) 99% (at 10 years)        5 y: 52% 10 y: 73%           48 (at 5 years) 27 (at 10 years)                    1
  Bruinsma et al. \[[@cit0016]\]      2018   15,101               65                   5.4                                                                 2.2                                                                                     62.8 (overall remaining on AS)                                                                        NR                                        NR                           58 (at 5 years) 39 (at 10 years) 23 (at 10 years)   37
  Stavrinides et al. \[[@cit0017]\]   2020   672                  LR: 62 FIR: 64       LR: 6 ROR: 6.9                                                      58                                                                                      85 (at 3 years)[^b^](#tf2-2){ref-type="table-fn"} 72 (at 5 years)[^b^](#tf2-2){ref-type="table-fn"}   NR                                        NR                           85 (at 3 years) 72 (at 5 years)                     0
  Tosoian et al. \[[@cit0018]\]       2020   1,818                VLR: 66 LR: 67       VLR: 4.6 LR: 5.9                                                    60                                                                                      93.2 (at 10 years)                                                                                    99.9% (at 10 years) 99.1% (at 10 years)   NR                           NR                                                  4

PSA -- prostate specific antigen, NR -- not reported, VLR -- very low risk, LR -- low risk, FIR -- favorable intermediate risk (Gleason 3+4)

the treatment rate was 60% in men who both did and did not meet strict AS clinical criteria

remained on an magnetic resonance-led active surveillance program

Creating a global consensus on how to monitor the patients with LR-CLPC on AS is one of the major goals of the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative \[[@cit0016]\]. We believe that with further joint efforts of both researchers and health or professional organizations, men diagnosed with LR-CLPC will benefit from reliable, evidence-based, and standardized protocols which would ensure the best safety outcomes and have the least negative impact on the quality of life.
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